Transcriptomic signatures of progression to TB disease among close contacts in Brazil
Simon C Mendelsohn,Bruno B Andrade,Stanley Kimbung Mbandi,Alice M S Andrade,Vanessa M Muwanga,Marina C Figueiredo,Mzwandile Erasmus,Valeria C Rolla,Prisca K Thami,Marcelo Cordeiro-Santos,Adam Penn-Nicholson,Afranio L Kritski,Mark Hatherill,Timothy R Sterling,Thomas J Scriba,Nicole Bilek,Yolundi Cloete,Mzwandile Erasmus,Michelle Fisher,Katie Hadley,Rieyaat Hassiem,Mark Hatherill,Lungisa Jaxa,Stanley Kimbung Mbandi,Simon C Mendelsohn,Faheemah Meyer,Vanessa M Muwanga,Onke Nombida,Adam Penn-Nicholson,Rodney Raphela,Thomas J Scriba,Alison September,Timothy R Sterling,Prisca K Thami,Ashley Veldsman,Alice Andrade,Bruno B Andrade,Brenda Carvalho,Marcelo Cordeiro-Santos,Marina Cruvinel Figueiredo,Adriano Gomes,Afranio L Kritski,Valeria C Rolla,Timothy R Sterling,the RePORT-South Africa and RePORT-Brazil Consortia
DOI: https://doi.org/10.1093/infdis/jiae237
2024-05-07
The Journal of Infectious Diseases
Abstract:Background Approximately 5% of people infected with Mycobacterium tuberculosis progress to tuberculosis (TB) disease without preventive therapy. There is a need for a prognostic test to identify those at highest risk of incident TB, so that therapy can be targeted. We evaluated host blood transcriptomic signatures for progression to TB disease. Methods Close contacts (≥4 hours exposure per week) of adult patients with culture-confirmed pulmonary TB were enrolled in Brazil. Investigation for incident, microbiologically-confirmed or clinically-diagnosed pulmonary or extra-pulmonary TB disease through 24 months of follow-up was symptom-triggered. Twenty previously validated blood TB transcriptomic signatures were measured at baseline by real-time quantitative PCR. Prognostic performance for incident TB was tested using receiver operating characteristic curve (ROC) analysis at 6, 9, 12, and 24 months of follow-up. Results Between June 2015 and June 2019, 1,854 close contacts were enrolled; Twenty-five progressed to incident TB, of whom 13 had microbiologically-confirmed disease. Baseline transcriptomic signature scores were measured in 1,789 close contacts. Prognostic performance for all signatures was best within 6 months of diagnosis. Seven signatures (Gliddon4, Suliman4, Roe3, Roe1, Penn-Nicholson6, Francisco2, and Rajan5) met the minimum World Health Organization target product profile (TPP) for a prognostic test through 6 months; three (Gliddon4, Rajan5, and Duffy9) through 9 months. None met the TPP threshold through 12 or more months of follow-up. Conclusions Blood transcriptomic signatures may be useful for predicting TB risk within 9 months of measurement among TB-exposed contacts, to target preventive therapy administration.
immunology,infectious diseases,microbiology